HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model

Anna L McNaughton, José Lourenço, Louise Hattingh, Emily Adland, Samantha Daniels, Anriette Van Zyl, Connie S Akiror, Susan Wareing, Katie Jeffery, M Azim Ansari, Paul Klenerman, Philip J R Goulder, Sunetra Gupta, Pieter Jooste, Philippa C Matthews

Research output: Contribution to journalArticle (Academic Journal)peer-review

12 Citations (Scopus)


BACKGROUND: Sustainable Development Goals set a challenge for the elimination of hepatitis B virus (HBV) infection as a public health concern by the year 2030. Deployment of a robust prophylactic vaccine and enhanced interventions for prevention of mother to child transmission (PMTCT) are cornerstones of elimination strategy. However, in light of the estimated global burden of 290 million cases, enhanced efforts are required to underpin optimisation of public health strategy. Robust analysis of population epidemiology is particularly crucial for populations in Africa made vulnerable by HIV co-infection, poverty, stigma and poor access to prevention, diagnosis and treatment.

METHODS: We here set out to evaluate the current and future role of HBV vaccination and PMTCT as tools for elimination. We first investigated the current impact of paediatric vaccination in a cohort of children with and without HIV infection in Kimberley, South Africa. Second, we used these data to inform a new parsimonious model to simulate the ongoing impact of preventive interventions. By applying these two approaches in parallel, we are able to determine both the current impact of interventions, and the future projected outcome of ongoing preventive strategies over time.

RESULTS: Existing efforts have been successful in reducing paediatric prevalence of HBV infection in this setting to < 1%, demonstrating the success of the existing vaccine campaign. Our model predicts that, if consistently deployed, combination efforts of vaccination and PMTCT can significantly reduce population prevalence (HBsAg) by 2030, such that a major public health impact is possible even without achieving elimination. However, the prevalence of HBV e-antigen (HBeAg)-positive carriers will decline more slowly, representing a persistent population reservoir. We show that HIV co-infection significantly reduces titres of vaccine-mediated antibody, but has a relatively minor role in influencing the projected time to elimination. Our model can also be applied to other settings in order to predict impact and time to elimination based on specific interventions.

CONCLUSIONS: Through extensive deployment of preventive strategies for HBV, significant positive public health impact is possible, although time to HBV elimination as a public health concern is likely to be substantially longer than that proposed by current goals.

Original languageEnglish
Pages (from-to)43
JournalBMC Medicine
Issue number1
Publication statusPublished - 21 Feb 2019


  • Adolescent
  • Adult
  • Child
  • Cohort Studies
  • Coinfection/epidemiology
  • Female
  • HIV Infections/epidemiology
  • Hepatitis B Vaccines/pharmacology
  • Humans
  • Infectious Disease Transmission, Vertical/prevention & control
  • Middle Aged
  • Young Adult


Dive into the research topics of 'HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model'. Together they form a unique fingerprint.

Cite this